The Aesthetic Revolution: Your Insider’s Guide to the Beauty Industry
The beauty industry is a multi-faceted domain, boasting a rich history and a promising future.…
3 years ago
Saudi Arabia-China Entrepreneurs Association signs MoU with Hong Kong Trade Development Council
Agreement signed at the at Belt and Road Summit to promote trade and business between…
3 years ago
Justin Sun Speaks at the Prestigious Milken Institute Asia Summit
Continuously promoting industry breakthroughs, Asia will become an important crypto center SINGAPORE - Media OutReach…
3 years ago
Play Over 550 Games For 30 Days On Zolaz Cloud Gaming Service For Free
SINGAPORE - Media OutReach - 16 September 2023 - Zolaz Cloud Gaming by M1 is…
3 years ago
Vietnam and China: comprehensive agricultural cooperation
GUANGXI, CHINA - Media OutReach - 16 September 2023 – In 2008, Vietnam and China…
3 years ago
SAGALIAM ACQUISITION CORP. ANNOUNCES EXECUTION OF DEFINITIVE BUSINESS COMBINATION AGREEMENT AND RECEIPT OF NASDAQ LISTING DELINQUENCY LETTER
New York, NY, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: “SAGAUâ€, “SAGAâ€,…
3 years ago
NSSC INVESTOR NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages NAPCO Security Technologies, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Initiated by the Firm – NSSC
NEW YORK--(BUSINESS WIRE)--$NSSC #NSSC--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers…
3 years ago
Gallium Semiconductor Expands Portfolio With First ISM CW Amplifier
The GTH2e-2425300P delivers best-in-class broadband efficiency (>72%) and RF performance for ISM applications in a…
3 years ago
AM Best Removes Under Review With Negative Implications Status and Affirms Credit Ratings of Hotai Insurance Co., Ltd.
HONG KONG--(BUSINESS WIRE)--AM Best has removed from under review with negative implications and affirmed the…
3 years ago
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
Recommendation based on DESTINY-Lung02 trial results, which showed Daiichi Sankyo and AstraZeneca’s ENHERTU achieved strong…
3 years ago